Will de van der Schueren

Will de van der Schueren joined Menzer Law Group in 2026. His legal practice focuses on the areas of personal injury, medical malpractice, wrongful death, vaccine injury, and insurance law.

Will earned his Bachelor of Science in Biochemistry from the University of Washington in 2012 and received his Juris Doctor from the University of Washington School of Law in 2023. He is licensed to practice law in the State of Washington and in the U.S. Court of Federal Claims.

Will’s legal practice is built upon years of scientific research experience and a deep understanding of complex technical and medical issues. Before joining Menzer Law Group, Will practiced as an Associate Attorney at a boutique intellectual property law firm based in Seattle, Washington, where he advised clients on complex intellectual property matters involving biotechnology, pharmaceuticals, and other life sciences technologies.

Prior to entering the legal profession, Will spent years working in scientific research. He has co-authored peer-reviewed scientific publications in leading journals, including Nature Structural & Molecular Biology and Cell. Through this work, Will developed a strong foundation for understanding complex medical and scientific evidence, along with a deep appreciation for the profound impact that medical and scientific issues can have on individuals and families.

Will lives just outside the city of Seattle with his wife, Melanie, and their two dogs. They enjoy spending time on the coast and in the mountains, golfing, and supporting Seattle sports teams.

Education

University of Washington School of Law, J.D., 2023
University of Washington, B.S., Biochemistry, 2012

Bar Admissions

Washington State Bar
United States Patent and Trademark Office (Patent Bar)

Professional Associations

Washington State Bar Association, 2023

Past Positions

Associate Attorney, Seed IP Law Group
Associate Scientist, Bluebird Bio
Research Technician, Fred Hutchinson Cancer Research Center

Published Works

Sauer, M.M., Tortorici, M.A., Park, YJ. et al. Structural basis for broad coronavirus neutralization. Nat Struct Mol Biol 28, 478–486 (2021). https://doi.org/10.1038/s41594-021-00596-4
Marcandalli J, Fiala B, Ols S, Perotti M, de van der Schueren WJ, et al. “Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus.” Cell, vol. 176, no. 6, 7 Mar. 2019, pp. 1420–1431., doi:10.1016/j.cell.2019.01.046.
Correnti C.E, Gewe M.M, Mehlin C, Bandaranayake A, Johnsen W, Rupert P, Brusniak M, Clarke M, Burke S, de van der Schueren WJ, et al. “Screening, large-scale production and structure-based classification of cystine-dense peptides.” Nat Struct Mol Biol 25, 270–278 (2018). https://doi.org/10.1038/s41594-018-0033-9
Correnti CE, Laszlo GS, de van der Schueren WJ, Godwin CD, Bandaranayake A, Busch MA, Gudgeon CJ, Bates OM, Olson JM, Mehlin C, Walter RB. “Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation.” Leukemia. 2018 May;32(5):1239-1243. doi: 10.1038/s41375-018-0014-3. Epub 2018 Jan 31. PMID: 29588544; PMCID: PMC5943151.
Peng T, Chanthaphavong RS, Sun S, Trigilio JA, Phasouk K, Jin L, Layton ED, Li AZ, Correnti CE, De van der Schueren WJ, et al. “Keratinocytes produce IL-17c to protect peripheral nervous systems during human HSV-2 reactivation.” J Exp Med. 2017 Aug 7;214(8):2315-2329. doi: 10.1084/jem.20160581. Epub 2017 Jun 29. PMID: 28663436; PMCID: PMC5551564.
Koh CY, Wetzel AB, de van der Schueren WJ, Hol WG. “Comparison of histidine recognition in human and trypanosomatid histidyl-tRNA synthetases.” Biochimie. 2014 Nov;106:111-20. doi: 10.1016/j.biochi.2014.08.005. Epub 2014 Aug 20. PMID: 25151410; PMCID: PMC4250371.
Koh CY, Kim JE, Wetzel AB, de van der Schueren WJ, Shibata S, Ranade RM, Liu J, Zhang Z, Gillespie JR, Buckner FS, Verlinde CL, Fan E, Hol WG. “Structures of Trypanosoma brucei methionyl-tRNA synthetase with urea-based inhibitors provide guidance for drug design against sleeping sickness.” PLoS Negl Trop Dis. 2014 Apr 17;8(4):e2775. doi: 10.1371/journal.pntd.0002775. PMID: 24743796; PMCID: PMC3990509.